share_log
  • Headlines
  • IX Biopharma Widens Net Loss by 12% in FY2024

IX Biopharma Widens Net Loss by 12% in FY2024

Singapore Business Review ·  Aug 27, 2024 16:51

Loss per share stood at $0.0141.

iX Biopharma reported a net loss by 12% to $10.8m in FY2024 from $9.6m a year ago.

Revenue for the period slipped 1% to $5.95m from $5.91m in FY2023, whilst gross profit fell 55% to $1.04m from $2.32m in FY2023.

Loss per share stood at $0.0141 from $0.0126 a year ago.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment
    Related Stocks Related Stocks
    Symbol Mini Chart Price
    IX Biopharma
    42C
    -- 0.021
    Log In for the Full List
    Investment Course
    Choose stocks based on financial reports
    Quickly master financial season learning guidelines
    When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
    How to view Tesla's performance in January 2025? Pay attention to these four key points.
    It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
    In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
    When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha